Jazz Pharma Q2 revenue $957M (+3% YoY); GAAP EPS $1.52 beats; raises FY guidance

Jazz Pharmaceuticals plc

2023-Q2 EPS reported $2.55 revenue$1,850,129,000

Q2 total revenue $957M (+3% YoY); GAAP net income $104.4M ($1.52 diluted EPS) vs $34.7M ($0.55) prior year.
Xywav sales $326.6M (+39% YoY); Epidiolex $202.2M (+15%); Rylaze $101.7M (+39%).
Raises FY2023 guidance: revenue $3.725-$3.875B; non-GAAP adjusted EPS raised to $18.15-$19.00 from $16.90-$17.85.
Repurchased $100M in shares under $1.5B program; $336M remaining as of June 30, 2023.
Combined oxybate revenue (incl. AG royalties) $491.8M (-2% YoY); Xyrem down 41% to $159.8M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Jazz Pharmaceuticals plc updated its the second quarter of 2023 guidance (raised).

Period: the second quarter of 2023
Guidance: raised
Result: reported results

Exact text from the filing

On August 9, 2023, Jazz Pharmaceuticals plc (the “Company”) issued a press release (the “Press Release”) announcing financial results for the Company for the quarter ended June 30, 2023.

View on SEC.gov

18 earnings releases filed in the last 30 days. Browse all earnings releases →

Jazz Pharmaceuticals plc filing history →

Source: SEC EDGAR

accession 0001232524-23-000036

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.